GTx says muscle drug fails in late-stage trials

(Reuters) – GTx Inc said its experimental drug to treat muscle wasting in cancer patients was not effective in improving body mass in late-stage trials. A 3-mg dose of the drug, enobosarm, was tested on about 325 patients with non-small cell lung cancer – the most common form of lung cancer. There is no approved cure for cancer-induced muscle wasting which causes decreased physical function, fatigue and weight loss. (Reporting by Pallavi Ail in Bangalore; Editing by Saumyadeb Chakrabarty)